Market Cap 16.11B
Revenue (ttm) 2.11B
Net Income (ttm) 404.39M
EPS (ttm) N/A
PE Ratio 39.84
Forward PE 38.50
Profit Margin 19.17%
Debt to Equity Ratio 0.00
Volume 163,200
Avg Vol 288,030
Day's Range N/A - N/A
Shares Out 28.17M
Stochastic %K 88%
Beta 1.43
Analysts Hold
Price Target $561.27

Company Profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical moni...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 513 579 9911
Fax: 513 579 0444
Address:
5375 Medpace Way, Cincinnati, United States
TrendDrivenAnalyst
TrendDrivenAnalyst Dec. 27 at 7:15 AM
$MEDP Sentiment increasingly tracks operational truth rather than guidance tone. Competitive advantages must begin to appear in core metrics. Credible progress tends to compress risk premiums. Investors will likely insist on proof before expanding exposure.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:09 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $571.86, exhibiting strong momentum but is overbought with an RSI of 72.01. The recent price action is close to the 60D high of $626.26, indicating potential resistance. Directional Bias: The stock is showing bullish tendencies, but the high RSI suggests a correction may be imminent. The MA30 (576.34) and MA50 (575.82) are slightly above the current price, indicating potential resistance levels. Trade Plan: - Suggested Entry: $570.00 - Stop Loss: $550.00 (3.7% below entry) - Take Profit Targets: 1. $590.00 (3.5% gain) 2. $610.00 (7.0% gain) 3. $670.00 (17.2% gain) Rationale: The first two targets allow for short-term gains while the third target provides a significant ROI, capitalizing on potential upward momentum if the stock breaks resistance. Monitor RSI and price action closely for adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:04 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $560.21, near the lower end of its 60-day range ($484.0 - $626.26). The RSI of 32.83 indicates that the stock is oversold, suggesting a potential reversal. Directional Bias: With the current price below both the 30-day MA (579.78) and the 50-day MA (571.48), the short-term trend is bearish. However, the oversold RSI indicates a likelihood of a rebound, providing a bullish bias for a short-term trade. Trade Plan: - Suggested Entry: $560.21 - Stop Loss: $540.00 (risking $20.21) - Take Profit Targets: 1. $580.00 (3.5% gain) 2. $600.00 (7.1% gain) 3. $655.00 (17% gain) The third target aligns with the 60-day high, providing a strong potential for profit. Monitor the trade closely, especially given the ATR of 15.3, which indicates volatility. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:50 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $558.74, significantly below its 60-day high of $626.26 and near its 60-day low of $484. The RSI at 25.54 indicates that the stock is oversold, suggesting potential for a reversal. The stock is also trading below its moving averages (MA30 at 582.31 and MA50 at 570.39), indicating bearish momentum but also providing resistance levels. Directional Bias: The oversold RSI suggests a bullish reversal may be imminent, especially if it can break above the MA30. Trade Plan: - Suggested Entry: $560.00 (slightly above the last close to confirm upward momentum) - Stop Loss: $540.00 (below recent support) - Take Profit Targets: 1. $580.00 (3.57% gain) 2. $600.00 (7.11% gain) 3. $655.00 (17% gain) This plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:03 PM
Barclays updates rating for Medpace Hldgs ( $MEDP ) to Underweight, target set at 485 → 525.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:23 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $557.9, with an RSI of 37.9 indicating potential oversold conditions. The stock is below both the 30-day MA of $584.35 and the 50-day MA of $569.29, suggesting a bearish trend. However, the recent low of $484.0 provides a strong support level, indicating potential for a reversal. Directional Bias: The RSI indicates that the stock may be due for a bounce, especially as it approaches the 60-day low. A reversal from this level could lead to upward momentum. Trade Plan: - Suggested Entry: $558.00 - Stop Loss: $540.00 (3.2% below entry) - Take Profit Targets: 1. $580.00 (3.9% gain) 2. $600.00 (7.6% gain) 3. $650.00 (16.5% gain) Target 3 offers a potential ROI of 16.5%, aligning with our goal of over 17%. Monitor for price action near targets for adjustments. https://privateprofiteers.com
0 · Reply
oakleighcastillo
oakleighcastillo Dec. 12 at 5:44 PM
$MIGI $MEDP Mainz Biomed is calm on the tape, no panic, just absorption around $1.01–$1.02, and I like that the narrative has multiple legs with PancAlert flashing 100% sensitivity and 95% specificity as bonus optionality
0 · Reply
IcePhoenix
IcePhoenix Dec. 12 at 12:02 AM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:17 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $566.59, showing a neutral RSI of 42.91, indicating potential for upward movement as it is below the overbought threshold. The price is positioned between the 60D high of $626.26 and low of $484.00, suggesting room for growth. Directional Bias: The price is below both the 30-day moving average (MA30) of $585.11 and the 50-day moving average (MA50) of $568.86, indicating a bearish trend in the short term. However, the RSI suggests that the stock may be oversold, presenting a potential reversal opportunity. Trade Plan: - Suggested Entry: $570.00 (slightly above current price to confirm upward movement) - Stop Loss: $550.00 (to limit risk) - Take Profit Targets: 1. $590.00 (3.45% ROI) 2. $610.00 (6.08% ROI) 3. $665.00 (17.35% ROI) This trade plan allows for a strategic entry with multiple profit-taking opportunities while managing risk effectively. https://privateprofiteers.com
0 · Reply
StoxWise369
StoxWise369 Dec. 11 at 3:55 PM
$BEAT ♦️♦️♦️New Cardio AI controls! New comer for Cardio Market! IMO “HeartBeam and Samsung have a strategic partnership focused on improving at-home cardiac care, combining HeartBeam's advanced AI-driven VECG (Vector Electrocardiogram) tech with Samsung's popular Galaxy smartwatches…” $ISRG $MEDP $BSX
0 · Reply
Latest News on MEDP
6 Healthcare Stocks With Strong Upward Momentum

Nov 18, 2025, 12:59 PM EST - 5 weeks ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH ELAN GH WGS


Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 1:37 PM EDT - 2 months ago

Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript


Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back

Oct 23, 2025, 11:15 AM EDT - 2 months ago

Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back


Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Oct 22, 2025, 4:15 PM EDT - 2 months ago

Medpace Holdings, Inc. Reports Third Quarter 2025 Results


Medpace: Return Of The Mack, With Double-Digit Revenue Growth

Aug 4, 2025, 2:25 AM EDT - 5 months ago

Medpace: Return Of The Mack, With Double-Digit Revenue Growth


Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 2:14 PM EDT - 5 months ago

Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript


Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 5 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

RXRX


Medpace Holdings, Inc. Reports Second Quarter 2025 Results

Jul 21, 2025, 4:15 PM EDT - 5 months ago

Medpace Holdings, Inc. Reports Second Quarter 2025 Results


Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Apr 22, 2025, 3:42 PM EDT - 8 months ago

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript


Medpace Holdings, Inc. Reports First Quarter 2025 Results

Apr 21, 2025, 4:15 PM EDT - 8 months ago

Medpace Holdings, Inc. Reports First Quarter 2025 Results


Medpace Holdings: It Might Be Time To Buy In

Apr 4, 2025, 8:14 AM EDT - 9 months ago

Medpace Holdings: It Might Be Time To Buy In


Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 5:40 PM EST - 11 months ago

Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript


MoneyShow's Best Investment Ideas For 2025: Part 6

Jan 24, 2025, 2:35 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2025: Part 6

ALLY FTI OS PTON UAMY VRT


TrendDrivenAnalyst
TrendDrivenAnalyst Dec. 27 at 7:15 AM
$MEDP Sentiment increasingly tracks operational truth rather than guidance tone. Competitive advantages must begin to appear in core metrics. Credible progress tends to compress risk premiums. Investors will likely insist on proof before expanding exposure.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:09 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $571.86, exhibiting strong momentum but is overbought with an RSI of 72.01. The recent price action is close to the 60D high of $626.26, indicating potential resistance. Directional Bias: The stock is showing bullish tendencies, but the high RSI suggests a correction may be imminent. The MA30 (576.34) and MA50 (575.82) are slightly above the current price, indicating potential resistance levels. Trade Plan: - Suggested Entry: $570.00 - Stop Loss: $550.00 (3.7% below entry) - Take Profit Targets: 1. $590.00 (3.5% gain) 2. $610.00 (7.0% gain) 3. $670.00 (17.2% gain) Rationale: The first two targets allow for short-term gains while the third target provides a significant ROI, capitalizing on potential upward momentum if the stock breaks resistance. Monitor RSI and price action closely for adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:04 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $560.21, near the lower end of its 60-day range ($484.0 - $626.26). The RSI of 32.83 indicates that the stock is oversold, suggesting a potential reversal. Directional Bias: With the current price below both the 30-day MA (579.78) and the 50-day MA (571.48), the short-term trend is bearish. However, the oversold RSI indicates a likelihood of a rebound, providing a bullish bias for a short-term trade. Trade Plan: - Suggested Entry: $560.21 - Stop Loss: $540.00 (risking $20.21) - Take Profit Targets: 1. $580.00 (3.5% gain) 2. $600.00 (7.1% gain) 3. $655.00 (17% gain) The third target aligns with the 60-day high, providing a strong potential for profit. Monitor the trade closely, especially given the ATR of 15.3, which indicates volatility. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:50 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $558.74, significantly below its 60-day high of $626.26 and near its 60-day low of $484. The RSI at 25.54 indicates that the stock is oversold, suggesting potential for a reversal. The stock is also trading below its moving averages (MA30 at 582.31 and MA50 at 570.39), indicating bearish momentum but also providing resistance levels. Directional Bias: The oversold RSI suggests a bullish reversal may be imminent, especially if it can break above the MA30. Trade Plan: - Suggested Entry: $560.00 (slightly above the last close to confirm upward momentum) - Stop Loss: $540.00 (below recent support) - Take Profit Targets: 1. $580.00 (3.57% gain) 2. $600.00 (7.11% gain) 3. $655.00 (17% gain) This plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:03 PM
Barclays updates rating for Medpace Hldgs ( $MEDP ) to Underweight, target set at 485 → 525.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:23 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $557.9, with an RSI of 37.9 indicating potential oversold conditions. The stock is below both the 30-day MA of $584.35 and the 50-day MA of $569.29, suggesting a bearish trend. However, the recent low of $484.0 provides a strong support level, indicating potential for a reversal. Directional Bias: The RSI indicates that the stock may be due for a bounce, especially as it approaches the 60-day low. A reversal from this level could lead to upward momentum. Trade Plan: - Suggested Entry: $558.00 - Stop Loss: $540.00 (3.2% below entry) - Take Profit Targets: 1. $580.00 (3.9% gain) 2. $600.00 (7.6% gain) 3. $650.00 (16.5% gain) Target 3 offers a potential ROI of 16.5%, aligning with our goal of over 17%. Monitor for price action near targets for adjustments. https://privateprofiteers.com
0 · Reply
oakleighcastillo
oakleighcastillo Dec. 12 at 5:44 PM
$MIGI $MEDP Mainz Biomed is calm on the tape, no panic, just absorption around $1.01–$1.02, and I like that the narrative has multiple legs with PancAlert flashing 100% sensitivity and 95% specificity as bonus optionality
0 · Reply
IcePhoenix
IcePhoenix Dec. 12 at 12:02 AM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:17 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $566.59, showing a neutral RSI of 42.91, indicating potential for upward movement as it is below the overbought threshold. The price is positioned between the 60D high of $626.26 and low of $484.00, suggesting room for growth. Directional Bias: The price is below both the 30-day moving average (MA30) of $585.11 and the 50-day moving average (MA50) of $568.86, indicating a bearish trend in the short term. However, the RSI suggests that the stock may be oversold, presenting a potential reversal opportunity. Trade Plan: - Suggested Entry: $570.00 (slightly above current price to confirm upward movement) - Stop Loss: $550.00 (to limit risk) - Take Profit Targets: 1. $590.00 (3.45% ROI) 2. $610.00 (6.08% ROI) 3. $665.00 (17.35% ROI) This trade plan allows for a strategic entry with multiple profit-taking opportunities while managing risk effectively. https://privateprofiteers.com
0 · Reply
StoxWise369
StoxWise369 Dec. 11 at 3:55 PM
$BEAT ♦️♦️♦️New Cardio AI controls! New comer for Cardio Market! IMO “HeartBeam and Samsung have a strategic partnership focused on improving at-home cardiac care, combining HeartBeam's advanced AI-driven VECG (Vector Electrocardiogram) tech with Samsung's popular Galaxy smartwatches…” $ISRG $MEDP $BSX
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:20 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $544.08, significantly below its 60-day high of $626.26, indicating potential for a rebound. The RSI at 31.35 suggests the stock is oversold, indicating a potential upward correction. Directional Bias: The stock is currently in a bearish trend, as indicated by its position below the 30-day (586.37) and 50-day (567.48) moving averages. However, the oversold RSI signals a possible reversal opportunity. Trade Plan: - Suggested Entry: $545.00 (slightly above the last close to confirm upward momentum) - Stop Loss: $520.00 (4.6% below entry to manage risk) - Take Profit Targets: 1. Target 1: $580.00 (6.4% gain) 2. Target 2: $600.00 (10.1% gain) 3. Target 3: $640.00 (17.5% gain) This trade plan offers a structured approach with a potential ROI exceeding 17% on the third target. Monitor price action closely and adjust as necessary. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:08 PM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $550.82, with an RSI of 35.97 indicating the stock is oversold, suggesting a potential reversal. The stock is below both the 30-day MA (588.17) and 50-day MA (566.64), indicating bearish momentum but also potential for upward correction. Directional Bias: Given the oversold RSI and proximity to the 60-day low (484.0), we anticipate a bullish reversal. The ATR of 18.13 suggests volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $553.00 - Stop Loss: $530.00 (4.17% below entry) - Take Profit Targets: 1. $580.00 (4.88% ROI) 2. $605.00 (9.40% ROI) 3. $645.00 (16.54% ROI) Target 3 provides a potential ROI of over 17%, aligning with our strategy for significant gains. Monitor the price action closely around the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:09 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $544.77, showing a bearish sentiment with an RSI of 31.24, indicating potential oversold conditions. The price is below both the 30-day MA of 591.6 and the 50-day MA of 564.36, suggesting a downward trend. However, the proximity to the 60-day low of 474.92 presents a potential reversal opportunity. Directional Bias: Despite the bearish indicators, the oversold RSI suggests a possible bounce. The price is near the lower end of its 60-day range, which could attract buyers. Trade Plan: - Suggested Entry: $545 - Stop Loss: $520 (4.6% below entry) - Take Profit Targets: - TP1: $570 (4.4% gain) - TP2: $600 (10.0% gain) - TP3: $640 (17.4% gain) Rationale: The targets are set based on resistance levels and the potential for recovery. The risk-reward ratio is favorable, with TP3 offering over 17% ROI. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
CatRocks
CatRocks Dec. 4 at 2:59 PM
$MEDP Back to $458?
0 · Reply
Gary29
Gary29 Dec. 2 at 1:59 PM
$MEDP doomed lol
0 · Reply
Gary29
Gary29 Dec. 2 at 1:59 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:32 AM
0 · Reply
solarpulsee
solarpulsee Nov. 30 at 8:40 PM
$MEDP Following a strong Q3 2025, one rating service upgraded MEDP to a “Strong Buy” under the framework of rising earnings estimates — suggesting near-term optimism on profit growth...
0 · Reply
solarpulsee
solarpulsee Nov. 30 at 7:37 PM
$MEDP Several recent analyses highlight strong fundamentals: good revenue growth, a robust cash-flow profile, and an expanding pipeline of “net new business awards,” which suggests that demand for Medpace’s clinical-research services remains healthy.
0 · Reply
solarpulsee
solarpulsee Nov. 30 at 7:36 PM
$MEDP Up 100% almost long term nice
0 · Reply